Description: Amphastar Pharmaceuticals, Inc., a generic and specialty pharmaceutical company, engages in the discovery, development, manufacture, and marketing of generic and proprietary pharmaceuticals, delivery systems, and active pharmaceutical ingredients. The company focuses on injectable, inhalation, and other categories of pharmaceutical products. Its products include Enoxaparin Sodium Injection, which is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism and the inpatient/outpatient treatment of acute deep vein thrombosis; Amphadase, a protein enzyme that is prepared from a highly purified bovine testicular hyaluronidase; Cortrosyn for Injection, a diagnostic agent that is used in the screening of patients presumed to have adrenocortocal insufficiency; and prefilled disposable emergency syringes for crash cart use. The company's products also include Lidocaine HCl Jelly, a preservative-free topical local anesthetic agent that is provided in a prefilled syringe; Naloxone HCl Injection for the complete or partial reversal of narcotic depression and diagnosis of suspected acute opioid overdose; and Phytonadione Injection (Vitamin K1) for newborns. In addition, it markets its drug development pipeline and patented technologies. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California with manufacturing subsidiaries/facilities in South El Monte, California; and West Roxbury and Canton, Massachusetts.
Home Page: www.amphastar.com
AMPH Technical Analysis
11570 6th Street
Rancho Cucamonga,
CA
91730
United States
Phone:
909 980 9484
Officers
| Name | Title |
|---|---|
| Dr. Ziping Luo Ph.D. | Chairman, Chief Scientist & COO |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, Pres, CEO, Chief Scientific Officer & Director |
| Mr. William J. Peters M.B.A. | CFO, Exec. VP of Fin., Treasurer & Director |
| Mr. Jacob Liawatidewi M.B.A. | Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director |
| Mr. Rong Zhou M.S. | Exec. VP of Production Center |
| Dan Dischner M.B.A. | VP of HR & Corp. Communication |
| Tony Marrs M.B.A., M.P.H. | Sr. VP of Regulatory Affairs & Clinical Operations |
| Mr. Peter Langosh | VP of Operational Improvement and VP of Internal Audit |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 18.8792 |
| Price-to-Book MRQ: | 2.7899 |
| Price-to-Sales TTM: | 2.839 |
| IPO Date: | 2014-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 1761 |